74 filings
Page 2 of 4
8-K
33ln 01wbco
4 May 23
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023
4:11pm
ARS
3m0wg9
28 Apr 23
Annual report to shareholders
4:12pm
DEFA14A
6kb 3qbctd553na2
27 Apr 23
Additional proxy soliciting materials
4:08pm
S-8
z7ir2opqz1bs3674lpr
28 Feb 23
Registration of securities for employees
5:30pm
8-K
fi72fvs9s17 86jz
28 Feb 23
Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022
4:11pm
8-K
tj5 4opxfjhxk7s46mvd
16 Dec 22
Lyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive Officer
4:02pm
8-K
r8lbb
8 Nov 22
Lyell Immunopharma Reports Recent Business Highlights and Third Quarter Financial Results
4:07pm
8-K
ow9 ezgl3
24 Oct 22
Termination of a Material Definitive Agreement
5:20pm
8-K
p91 40malawz
6 Oct 22
Regulation FD Disclosure
4:37pm
S-3ASR
3gz 73ymjgppp6nake
4 Aug 22
Automatic shelf registration
5:29pm
8-K
p1lsf8kf6x0619gv
4 Aug 22
Lyell Immunopharma Reports Second Quarter Financial Results and Business Highlights
4:16pm
8-K
j1x7fl2 igh
13 Jun 22
Submission of Matters to a Vote of Security Holders
4:54pm
8-K
scyizf9ce3bfj9oq7eu
10 May 22
Lyell Immunopharma Reports First Quarter Financial Results and Business Highlights
4:14pm
DEF 14A
juriplm5xdez
28 Apr 22
Definitive proxy
4:11pm